Clorox (CLX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
Werte in diesem Artikel
Clorox (CLX) reported $1.67 billion in revenue for the quarter ended March 2025, representing a year-over-year decline of 8.1%. EPS of $1.45 for the same period compares to $1.71 a year ago.The reported revenue represents a surprise of -2.67% over the Zacks Consensus Estimate of $1.71 billion. With the consensus EPS estimate being $1.57, the EPS surprise was -7.64%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.Here is how Clorox performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Organic Revenue Growth - Health and Wellness: 3% compared to the -1.9% average estimate based on four analysts. Organic Revenue Growth - International: 2% compared to the 6% average estimate based on four analysts. Organic Revenue Growth - Lifestyle: -3% compared to the 0.3% average estimate based on four analysts. Organic Revenue Growth - Household: -11% versus the four-analyst average estimate of -1.5%. Organic Sales Growth: -2% versus 1.2% estimated by four analysts on average. Net Revenue- Health and Wellness: $630 million compared to the $597.23 million average estimate based on four analysts. The reported number represents a change of +3.5% year over year. Net Revenue- International: $263 million compared to the $258.40 million average estimate based on four analysts. The reported number represents a change of -15.2% year over year. Net Revenue- Lifestyle: $306 million versus $314.14 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -2.9% change. Net Revenue- Household: $469 million versus $515.48 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -10.8% change. Income before income taxes- Health and Wellness: $169 million versus the two-analyst average estimate of $176.17 million. Income before income taxes- Corporate and Other: -$55 million compared to the -$68.49 million average estimate based on two analysts. Income before income taxes- International: $31 million compared to the $27.86 million average estimate based on two analysts. View all Key Company Metrics for Clorox here>>>Shares of Clorox have returned -3.3% over the past month versus the Zacks S&P 500 composite's +0.4% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.Only $1 to See All Zacks' Buys and SellsWe're not kidding.Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent.Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators,and more, that closed 256 positions with double- and triple-digit gains in 2024 alone.See Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report The Clorox Company (CLX): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks
Übrigens: Clorox und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und als Geschenk eine Gratisaktie erhalten.
Ausgewählte Hebelprodukte auf Clorox
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Clorox
Der Hebel muss zwischen 2 und 20 liegen
Name | Hebel | KO | Emittent |
---|
Name | Hebel | KO | Emittent |
---|
Quelle: Zacks
Nachrichten zu Clorox Co., The
Analysen zu Clorox Co., The
Datum | Rating | Analyst | |
---|---|---|---|
02.05.2019 | Clorox Hold | Deutsche Bank AG | |
14.12.2017 | Clorox Hold | Deutsche Bank AG | |
09.01.2017 | Clorox Equal Weight | Barclays Capital | |
16.12.2016 | Clorox Outperform | BMO Capital Markets | |
03.11.2016 | Clorox Sector Perform | RBC Capital Markets |
Datum | Rating | Analyst | |
---|---|---|---|
16.12.2016 | Clorox Outperform | BMO Capital Markets | |
06.02.2015 | Clorox Buy | Argus Research Company | |
05.12.2014 | Clorox Buy | Argus Research Company | |
09.07.2012 | Clorox kaufen | Euro am Sonntag | |
16.02.2011 | Clorox outperform | RBC Capital Markets |
Datum | Rating | Analyst | |
---|---|---|---|
02.05.2019 | Clorox Hold | Deutsche Bank AG | |
14.12.2017 | Clorox Hold | Deutsche Bank AG | |
09.01.2017 | Clorox Equal Weight | Barclays Capital | |
03.11.2016 | Clorox Sector Perform | RBC Capital Markets | |
05.05.2016 | Clorox Neutral | B. Riley & Co., LLC |
Datum | Rating | Analyst | |
---|---|---|---|
04.05.2016 | Clorox Sell | UBS AG | |
03.11.2015 | Clorox Sell | UBS AG | |
07.10.2015 | Clorox Underweight | Barclays Capital | |
23.09.2014 | Clorox Sell | B. Riley & Co., LLC | |
03.02.2006 | Update Clorox Co., The: Sell | Oppenheimer |
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Clorox Co., The nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen